TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03273569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDI-UC protocol
Description: Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
Study: NCT03088085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-mobilization
Description: Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
Study: NCT00533091

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks.
Study: NCT01453387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2015103B
Description: Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2015103B
Description: Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
Study: NCT02680678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colloid Preload
Description: preload infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colloid co-load
Description: co-load infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid preload
Description: preload infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Co-load
Description: co-load infusion
Study: NCT03954678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Group
Description: Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
Study: NCT03443947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue depressor group
Description: using a tongue depressor to assess airway score without tongue protrusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: airway assessment after tongue protrusion
Study: NCT01479348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Description: 18FdCyd radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine intravenous (IV)
Description: Total dose of THU = 350 mg/m\^2, IV
Study: NCT02202330

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video Arm
Description: 1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Arm
Description: 1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions.
Study: NCT01479348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine intravenous (IV)
Description: Total dose of THU = 350 mg/m\^2, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (oral)
Description: Total dose of THU is 3000 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (oral)
Description: Total dose of THU is 3000 mg, oral

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/Computed tomography (CT)
Description: One prior CT and 3 sequential whole body PET

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/Computed tomography (CT)
Description: One prior CT and 3 sequential whole body PET
Study: NCT00457405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 200mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 200mg twice daily
Study: NCT04057209

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Vocal Cord Irradiation (SVCI)
Description: The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)
Description: The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin.
Study: NCT03663452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)
Description: TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure training
Description: Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
Study: NCT03011229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro Core Needle
Description: Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medtronic Sharkcore Needle
Description: Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
Study: NCT00412529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Telbivudine 600 mg once daily for 12 weeks.
Study: NCT03224286

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.

Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.
Study: NCT02571348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-osteoperforation
Description: micro-osteoperforation with mini implant at different interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-osteoperforation
Description: micro-osteoperforation with mini implant at different interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-osteoperforation
Description: micro-osteoperforation with mini implant at different interval
Study: NCT01191814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal stent
Description: Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stent
Description: Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
Study: NCT03293654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US licenced Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU approved Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Study: NCT01492673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Topotecan, and Bevacizumab
Description: The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
Study: NCT01761734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text message
Study: NCT03389945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25G Dural Puncture Epidural Block
Description: Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 27G Dural Puncture Epidural Block
Description: Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space.
Study: NCT01284504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg tablet oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, tab
Study: NCT04338490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback mannequim
Description: The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
Study: NCT00828464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate
Description: Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
Study: NCT04398732

Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study: NCT03881709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using an E-Book
Description: The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
Study: NCT01727089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Description: Given IV
Study: NCT03004209

Intervention type: DRUG
Group type: OTHER
Intervention: Erythropoietin
Description: three times per a week 100IU / k
Study: NCT01727089

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study: NCT02197156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg HC / 325 mg APAP
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single dose
Study: NCT01727089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02321592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFM13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFM13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFM13
Study: NCT01636492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin
Description: Single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral dose
Study: NCT02886702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.05%
Description: Tazarotene Cream 0.05% to cover only the lesions with a thin film.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAZORAC® (tazarotene) Cream 0.05%
Description: TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) to cover only the lesions with a thin film.
Study: NCT03633279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid
Description: Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
Study: NCT03697590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No curettage
Description: Standard PDT without curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: Standard PDT
Study: NCT03874962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine oral cleaning and professional oral care group
Description: Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
Study: NCT02346318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Kushen Injection
Description: Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
Study: NCT04735302

Intervention type: OTHER
Intervention: Radiographic Feature
Description: Radiographic rewiev

Intervention type: OTHER
Intervention: Radiographic Feature
Description: Radiographic rewiev
Study: NCT00770367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone then Placebo
Description: Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Pioglitazone
Description: Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
Study: NCT00070525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT05084326

Intervention type: PROCEDURE
Intervention: Engagement of fetal head as a predictor of a successful vaginal delivery
Description: In addition to the fetal lie, presentation, and position, the level or station of the presenting part in the maternal pelvis is an important factors in the labor process.~In primigravida, Delayed engagement of fetal head has been theorized that it is more likely in women with a possible cephalo-pelvic disproportion, so far they are associated with higher risk of cervical dystocia, which led to increased rate of caesarean section.
Study: NCT02178332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yhteispeli, whole school programme

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two theoretical lectures
Study: NCT02857153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil
Description: If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil
Description: If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level MAP
Description: MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-level MAP
Description: MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
Study: NCT00445718

Intervention type: PROCEDURE
Intervention: computed tomography

Intervention type: PROCEDURE
Intervention: 3-Tesla magnetic resonance imaging

Intervention type: PROCEDURE
Intervention: Abdominal Sonogram
Description: Sonogram of the abdomen area
Study: NCT03633279

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)